GRAIL, Inc. (GRAL) Q3 2025 10-Q Quarterly Report
GRAIL, Inc. (GRAL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
GRAIL, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Samsung Investment closing uncertainty due to pending CFIUS regulatory approval and negotiation of Korea-focused collaboration agreements, affecting expected $110M proceeds
- • Updated risk: FDA LDT regulation vacated by court in March 2025, creating uncertainty in marketing authorization process and potential need to modify Galleri test configurations
- • Regulatory risk: FDA may require additional clinical data delaying or narrowing Galleri PMA approval, impacting commercialization and reimbursement timelines
- • Operational risk: Post-Dec 2024 updated Galleri test version faces increased turnaround times, re-processing costs, and sample failures, possibly harming reputation and revenue
- • Financial risk: Increased international exposure, including suppliers in China, Mexico, Europe, with risks from tariffs, trade restrictions, currency fluctuations, and geopolitical instability
Get deeper insights on GRAIL, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.